Psilocybin Effects on Healthy Aging Biomarkers and Purpose in Life (LONG-LIFE)

The LONG-LIFE study is a randomized Phase I, dose-ranging trial designed to evaluate whether psilocybin impacts aging-related biomarkers, cognitive function, and purpose/meaning in life in medically stable older adults. Up to 50 participants will be enrolled aged 60-80 who will be randomized with equal allocation to one of four intervention groups: (1) receipt of one 25 mg dose of psilocybin; (2) receipt of two 25 mg doses of psilocybin separated by four weeks; (3) receipt of three 25 mg doses, with each dose separated by four weeks; or (4) wait-list comparator condition that does not receive psilocybin. Biomarkers of aging, cognitive performance, and behavioral measures will be assessed at baseline and longitudinally over a 12-month follow-up period. The primary endpoint occurs at the Week 16 visit. Participants randomized to the wait-list condition will be offered a single 25 mg dose of psilocybin following conclusion of the 12-month follow-up period. Findings from this Phase I study will inform dose selection for a Phase II study should results indicate a potential impact of…

• Change in Epigenetic/Biological Clock Profiling from Baseline to Week 4 and Week 16
• Change in Purpose in Life (PIL) from Baseline to Week 4 and Week 16

1. Study completion expected

   Dec 2028

2. Primary completion expected

   Apr 2028

3. Expected to start

   Dec 2026

4. Last registry update

   13 Oct 2026

5. Registered

   22 Jul 2026